Anlon Healthcare Limited demonstrated robust financial performance in Q3 FY26, marking a significant turnaround in its growth trajectory. The pharmaceutical company, specializing in high-purity pharmaceutical intermediates and APIs, reported impressive year-on-year improvements across key financial metrics.

Financial Performance Highlights

The company's Q3 FY26 results showcased exceptional growth momentum:

For the nine-month period, the performance was equally impressive:

Strategic Expansion and Acquisitions

Anlon Healthcare has embarked on an aggressive inorganic growth strategy through strategic acquisitions. The company has completed the acquisition of Apiqo Organic and is in the process of acquiring Bizotic Life Science. These acquisitions are expected to significantly enhance the company's manufacturing capacity and market reach.

Combined Capacity Enhancement:

• Current combined installed capacity: 1,400 to 1,600 metric ton per annum
• Planned greenfield expansion: Additional 800 to 1,000 metric ton capacity
• Apiqo organic expansion: 500 to 600 metric ton per annum
• Anlon facility expansion: 1,200 to 1,300 metric ton per annum

Revenue Projections and Growth Targets

Management outlined ambitious revenue targets supported by strong order book visibility:

The company has committed to achieving approximately 30% revenue CAGR over the next 3 years, supported by expanding presence in regulated markets and increasing CDMO engagements.

Operational Excellence and Market Position

Anlon Healthcare maintains a strong operational foundation with its Rajkot facility operating at healthy utilization levels above 90%. The company's research-driven approach is supported by 21 DMF filings and presence across 15 countries. Currently, the company is developing 3 molecules for 2 global innovator companies, reinforcing its long-term strategy to build a scalable custom manufacturing platform.

Key Operational Metrics:

• Current facility utilization: Over 90%
• Order book for existing plant (FY27): ₹180-190 crore
• Apiqo confirmed order book: ₹125-130 crore
• Expected commercialization: 6-7 key molecules from 21 DMF filings

Margin Sustainability and Financial Outlook

The company has demonstrated strong margin discipline across its operations. Management confirmed sustainable EBITDA margins of 35% for domestic markets and targeting 50% for regulated markets. The blended margin profile across all facilities is expected to remain between 30-33% EBITDA margin.

Working Capital Optimization:

• Target working capital days: Reduction from current 290 days to 180-185 days by FY26 end
• Further improvement to 150-160 days in FY27
• Expected positive operating cash flow by FY27

The company plans to fund its ₹100-120 crore greenfield expansion through a combination of internal cash flows (₹40-50 crore) and bank debt (₹50-60 crore), maintaining a conservative debt-to-equity ratio of 0.5 to 0.55.

Anlon Healthcare Limited has released its comprehensive investor presentation for Q3 and nine months of FY26, following the scheduled earnings conference call on February 19, 2026. The pharmaceutical company shared detailed financial results and strategic insights for the period ended December 31, 2025, demonstrating robust growth across key performance metrics.

Q3 FY26 Financial Performance

The company delivered exceptional financial results in Q3 FY26, showcasing significant year-over-year improvements across all major parameters.

Nine Months FY26 Consolidated Results

The nine-month performance further reinforced the company's strong growth trajectory with substantial improvements in profitability metrics.

Conference Call and Investor Presentation Details

The earnings conference call was conducted on February 19, 2026, at 4:00 PM IST via Zoom Webinar, led by Mr. Punit Rasadia, Chairman & Managing Director. The comprehensive investor presentation has been uploaded on the company's website and can be accessed at https://www.anlon.in/reports.php?subid=15&name=Investor-Meet .

Business Highlights and Growth Metrics

Anlon Healthcare showcased impressive operational achievements in its investor presentation, highlighting its expanding global footprint and diversified product portfolio.

Strategic Growth Outlook

The company outlined ambitious expansion plans with combined installed capacity expected to reach 1,400-1,600 MTPA post expansion. Management targets 3-5 DMF filings in FY 2026-27 to strengthen regulated-market penetration and anticipates launching 7 new APIs across additional therapeutic categories. The company is positioned to deliver approximately 30% revenue CAGR over the next three years, supported by acquisitions and new product launches, while maintaining sustainable EBITDA margins of 25-30%.